Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intrathecal triple chemotherapy
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Intrathecal
01
Overview
Intrathecal triple chemotherapy is a combination regimen typically consisting of methotrexate, cytarabine, and a corticosteroid (such as hydrocortisone or prednisolone). It is administered directly into the subarachnoid space via lumbar puncture to provide prophylaxis or treatment for central nervous system (CNS) involvement in hematologic malignancies. In the context of Daiichi Sankyo's clinical development of quizartinib for pediatric and young adult patients with FLT3-ITD mutated acute myeloid leukemia (AML), this regimen is utilized as a standard-of-care CNS prophylaxis. The components work synergistically: methotrexate and cytarabine act as antimetabolites that interfere with DNA synthesis in rapidly dividing cancer cells, while the corticosteroid provides lympholytic effects and reduces the risk of chemical arachnoiditis associated with intrathecal injections.
- Other names
- IT triple chemotherapyTITTriple intrathecal therapyIntrathecal triple therapyIT3IT-3IT 3
02
Targets
GR (Glucocorticoid receptor)DHFR (Dihydrofolate reductase)DNA polymerase family
Beyond the preview
Go deeper on intrathecal triple chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intrathecal triple chemotherapy.